Chemotherapeutic agents are largely phase or cycle specific and therefore inactive against cells in the resting phase of the cell cycle. Drugs would be more effective if they were independent of cell growth whilst maintaining specificity to the tumour cells. Antibody targeting of liposome encapsulated drugs is highly specific (Gray et al., 1988) but their cytotoxicity is limited by cell cycle kinetics and the rate of internalisation of the liposomes. This varies widely depending on the target antigen, liposome size and composition and in some cells despite excellent liposome attachment no toxicity occurs (Machy et al., 1982) . However, a liposome encapsulated agent which does not require internalisation but can exert its cytotoxic action from the cell surface would be independent of this variable. If in addition it were toxic to resting tumour cells a more universal and effective drug targeting system could be envisaged.
Cancer chemotherapy depends on agents which are selective in their activity against malignant cells, and progress results from the deployment of new compounds with increased selectivity or new ways of administering existing agents.
Chemotherapeutic agents are largely phase or cycle specific and therefore inactive against cells in the resting phase of the cell cycle. Drugs would be more effective if they were independent of cell growth whilst maintaining specificity to the tumour cells. Antibody targeting of liposome encapsulated drugs is highly specific (Gray et al., 1988 ) but their cytotoxicity is limited by cell cycle kinetics and the rate of internalisation of the liposomes. This varies widely depending on the target antigen, liposome size and composition and in some cells despite excellent liposome attachment no toxicity occurs (Machy et al., 1982) . However, a liposome encapsulated agent which does not require internalisation but can exert its cytotoxic action from the cell surface would be independent of this variable. If in addition it were toxic to resting tumour cells a more universal and effective drug targeting system could be envisaged.
Phthalocyanine dyes are such a class of compounds (reviewed by Spikes, 1986) , whose cytotoxic action is thought to be primarily by generation of free radical singlet oxygen on exposure to light of specific wavelengths (Brasseur et al., 1985) . Sulphonated aluminium phthalocyanine (AlSPc) was encapsulated in liposomes bearing the monoclonal antibody 791T/36 and tested for photocytotoxicity against an osteosarcoma cell line 791T. This demonstrated rapid and highly specific cell killing in conditions which favoured the prevention of liposome internalisation by the cells.
Materials and methods

Cells
The phototoxicity of AISPc liposomes was tested in an osteosarcoma cell line with targeting antibody a mouse monoclonal 79IT/36 (subclass IgG 2b), raised against an epitope expressed on this line. Both cell line and antibody are well characterised and documented (Garnett et al., 1983; Perkins et al., 1985; Roe et al., 1985 Figure 1 shows that AlSPc photosensitised liposomes are only toxic to 791 T and C1 70 cancer cells when both targetted by antibody and exposed to red light (7, 8, 9) . Targeted AlSPc liposomes at 2.5 ug ml-1 were less toxic for C170 cells than for 791T cells (7.9) (PA0.005), but at 4.25 ,ug ml-1 (8,9) were equally toxic (no significant difference). Free AlSPc at concentrations of 2.5 and 25 tg ml-1 and all controls showed no significant toxicity whether irradiated with red light or not. Purification of AlSPc AlSPc was found to be a mixture of isomeric mono, di-, triand tetra-sulphonated forms which yielded many fractions on TLC, their position depending on their degree of solubility. A partial purification was performed as described in Materials and methods in order to give a more uniform and polar compound which was more suitable for encapsulating in the aqueous compartment of liposomes than the original mixture. HPLC of the purified fraction showed the presence of several peaks and suggested that it was composed mainly of tetra-and tri-sulphonated AlSPc.
Immunofluorescence analysis of cells Figure 3 shows that antigens or receptors are internalised and some are shed from the surface and are thus unsuitable for drug delivery.
AlSPc and other photosensitisers, for example chlorin e6 (Oseroff et al., 1986) do not necessarily need internalisation to be effective cytotoxic agents. In the present experiments conditions were used (incubtion at 4°C) that would not favour the kinetics of endocytosis or antigen shedding; therefore AlSPc would not gain access to the interior of the cell. The effect of targeting the AlSPc in liposomes therefore seems to be to concentrate the photosensitiser in sufficient proximity to the cell for it to have a cytotoxic action after light activation. It is possible that the liposome membrane is destroyed in the process. The main target sites for the active entity are probably the cell membrane and nearby cytoplasmic components which are attacked by singlet oxygen after its generation and diffusion from the lysed liposome. Singlet oxygen causes damage to cells by oxidation of biological molecules important for the integrity and functioning of the cells such as phospholipids, cholesterol, amino acids and nucleic acids (Grossweiner, 1981) . The postulated mechanism of action is thus similar to the lytic action of the complement system on the integrity of the cell membrane, and therefore, unlike many cytotoxic drugs AlSPc is able to destroy resting or slow growing cancer cells as well as actively dividing cells, which suggests it has the potential of a potent anticancer agent.
The phototoxic action of AlSPc is very rapid compared with drugs which must be internalised to cause toxicity. After 4 h incubation of 791T cells at 37°C only 30% of 791T/36 on the surface is internalised under saturating conditions (Huehns, 1986) . Any drug attached to the antibody is likely to take a similar time to gain access to the cell. By comparison, production of free radicals on illumination of 791T/36 bound liposomes containing AlSPc is practically instantaneous.
It is uncertain to what degree singlet oxygen will be able to damage zadjacent cells. The mean distance a singlet oxygen molecule can diffuse during its lifetime has been quoted as 1,000 A (Lindig & Rodgers, 198 1; Grossweiner, 198 1) . It has been suggested that this is too short a distance for diffusion to neighbouring cells (Yemul et al., 1987) anti-mouse antibody would be more versatile since it ensures binding to all Ig subclasses whereas protein A has restricted binding at physiological pH. Of course, where rat or any other species of monoclonal antibody are used the appropriate anti-species antibody must be attached to the liposome.
Most drug-Ab conjugates or liposome-Ab targeted drugs have had reasonable success as cytotoxic agents in vitro, but not in vivo, due to rapid uptake by the reticulo endothelial system, which prevents the drug reaching the target (Weinstein, 1984) , though some success has been achieved by exploiting the uptake of phthalocyanine containing liposomes by low density lipoproteins (LDL), and their subsequent delivery to tumour tissues with high LDL receptor expression (Reddi et al., 1987) . However, in some situations, such as treatment of malignancies affecting the body cavities, for example ovarian carcinoma, where ex vivo manipulations of cells are involved such as bone marrow transplantation, or where the affected organ is accessible to instillation, such as the bladder, they can still have an important role to play. This is particularly so in conditions where current treatment is inadequate, such as advanced ovarian carcinoma, or in autologous bone marrow transplantation (ABMT) where it would be used for purging as, for example, in multiple myeloma.
Intraperitoneal treatment of ovarian carcinoma has been attempted with limited success by administration of chemotherapeutic agents at much higher concentrations than would be given systemically (Richardson et al., 1985) . An advantage of such treatment is lower systemic toxicity, but there are local side effects due to free cytotoxic drug. With our liposome system tumour cells would be targeted by monoclonal antibodies and the normal peritoneum would be protected from non-specific uptake by the insulating effects of the encapsulating lipid. Intraperitoneal photodynamic therapy (PDT) of ovarian cancer would be feasible by i.p. injection of Ab targeted AlSPc liposomes followed by laser light delivered by quartz fibre for photoactivation.
This technique may also be widely applicable for the ex vivo purging of residual disease from the bone marrow of patients undergoing ABMT after high dose chemotherapy or total body irradiation to eliminate bulk disease. Pharmacological agents have been used to purge marrow from patients with lymphoma and leukaemia, but they lack selectivity and are equally toxic to normal haemopoietic cells (Singer & Linch, 1987) . With the right combination of monoclonal antibodies it should be possible to target and destroy tumour cells in bone marrow while sparing the normal haemopoietic precursor cells necessary for re-engraftment.
Purging is not thought to be necessary for ABMT where bulk disease can be satisfactorily eliminated and there is no detectable disease in the marrow. However, where there is marked infiltration of tumour cells in the bone marrow, as in multiple myeloma, then purging with antibody targeted AlSPc liposomes might offer a better chance of recovery without relapse.
Finally, it has been shown that monoclonal antibodies (produced against antigens of human bladder transitional cell carcinoma) bind preferentially to tumour rather than normal mucosa after intravesical injection (Chopin & deKernion, 1986) . Targeting AISPc-liposomes with such antibodies could provide an alternative route for treatment of bladder tumours.
Thanks to Russel Svenson of the Royal Institution, London for advice on the purification of AlSPc and for running the HPLC. This work was supported by a grant from Bloomsbury Health Authority.
